TRex Bio, Inc. (TRXB): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:04 ET
- Event date
- 2026-11-13
- Accession no.
- 0001193125-26-460588
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
TRexBio reports third quarter 2026 results, IPO proceeds and clinical updates
TRexBio reported a third quarter net loss of $13.2 million, compared to $7.9 million for the third quarter of 2025. Following its October 2026 IPO, the company expects its cash resources to fund operations and capital expenditure requirements into the second half of 2029. TRB-061 Phase 1b topline data are expected in mid-2027.
- Net loss was $13.2 million for the third quarter of 2026, compared to $7.9 million for the third quarter of 2025.
- Cash, cash equivalents and marketable securities totaled $78.2 million as of September 30, 2026, excluding IPO proceeds.
- The October 2026 IPO generated approximately $133.5 million in gross proceeds and approximately $119.0 million in net proceeds.
- TRB-061 Phase 1b topline data in atopic dermatitis are expected in mid-2027.
earningsequity offeringproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | ck0002139097-20261113.htm |
| EX-99.1 | EX-99.1 | ck0002139097-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.